Presentation ACC 2025 Dual Antiplatelet Therapy After PCI According To Bleeding Risk: HOST-BR RCT Presenter: Hyo-Soo Kim March 29, 2025 REGISTER for free or LOG IN to view this content Coronary Presentation ACC 2025 Up Next Presentation ACC 2025 Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial Presenter: Darren K. McGuire March 29, 2025 More slides + Presentation ACC 2025 Advance-HTN: Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension Presenter: Luke Laffin March 29, 2025 Presentation ACC 2025 Dapagliflozin after Transcatheter Aortic Valve Implantation Presenter: Sergio Raposeiras-Roubin March 29, 2025 We Recommend
Presentation ACC 2025 Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial Presenter: Darren K. McGuire March 29, 2025
Presentation ACC 2025 Advance-HTN: Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension Presenter: Luke Laffin March 29, 2025
Presentation ACC 2025 Dapagliflozin after Transcatheter Aortic Valve Implantation Presenter: Sergio Raposeiras-Roubin March 29, 2025